EA200600648A1 - Производные пурина, ингибирующие репликацию вич - Google Patents

Производные пурина, ингибирующие репликацию вич

Info

Publication number
EA200600648A1
EA200600648A1 EA200600648A EA200600648A EA200600648A1 EA 200600648 A1 EA200600648 A1 EA 200600648A1 EA 200600648 A EA200600648 A EA 200600648A EA 200600648 A EA200600648 A EA 200600648A EA 200600648 A1 EA200600648 A1 EA 200600648A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
radical
purin
derivatives
hiv replication
Prior art date
Application number
EA200600648A
Other languages
English (en)
Other versions
EA009734B1 (ru
Inventor
Поль Адриан Ян Жанссен
Паулус Йоаннес Леви
Марк Рене Де Жонж
Люсьен Мария Хенрикус Койманс
Фредерик Франс Дезире Дайер
Ян Херес
Хендрик Мартен Винкерс
Рубен Герардус Жорж Лендерс
Дирк Альфонс Лео Ванденпют
Original Assignee
Янссен Фармацевтика Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н. В. filed Critical Янссен Фармацевтика Н. В.
Publication of EA200600648A1 publication Critical patent/EA200600648A1/ru
Publication of EA009734B1 publication Critical patent/EA009734B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Abstract

Данное изобретение относится к применению соединения формулы (I) для производства лекарственного средства для профилактики или лечения инфекции ВИЧ, где соединением формулы (I) является соединение формулы (I), его N-оксид, фармацевтически приемлемая аддитивная соль, четвертичный амин или стереохимически изомерная форма, где А и В, каждый, представляют радикал формулы (а) или (b) и где -C-D-представляет двухвалентный радикал формулы -N=CH-NR- (с-1) или -NR-CH=N- (c-2), при условии что, когда А представляет радикал формулы (а), тогда В представляет радикал формулы (b), и когда А представляет радикал формулы (b), тогда В представляет радикал формулы (а).
EA200600648A 2003-09-25 2004-09-21 Производные пурина, ингибирующие репликацию вич EA009734B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350659 2003-09-25
PCT/EP2004/052262 WO2005028479A2 (en) 2003-09-25 2004-09-21 Hiv replication inhibiting purine derivatives

Publications (2)

Publication Number Publication Date
EA200600648A1 true EA200600648A1 (ru) 2006-08-25
EA009734B1 EA009734B1 (ru) 2008-02-28

Family

ID=34354400

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600648A EA009734B1 (ru) 2003-09-25 2004-09-21 Производные пурина, ингибирующие репликацию вич

Country Status (19)

Country Link
US (1) US8026245B2 (ru)
EP (1) EP1668011B1 (ru)
JP (1) JP5506751B2 (ru)
KR (1) KR20060121878A (ru)
CN (1) CN100475815C (ru)
AP (1) AP2006003517A0 (ru)
AT (1) ATE500254T1 (ru)
AU (1) AU2004274185B2 (ru)
BR (1) BRPI0414791A (ru)
CA (1) CA2535313C (ru)
DE (1) DE602004031641D1 (ru)
EA (1) EA009734B1 (ru)
ES (1) ES2361835T3 (ru)
IL (1) IL174467A0 (ru)
MX (1) MXPA06002069A (ru)
NO (1) NO20061788L (ru)
TW (1) TW200518758A (ru)
WO (1) WO2005028479A2 (ru)
ZA (1) ZA200602440B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
CN1997644A (zh) * 2004-03-02 2007-07-11 神经能质公司 被芳基取代的嘌呤类似物
ES2380604T3 (es) 2004-08-25 2012-05-16 Ardea Biosciences, Inc. S-triazolil alfa-mercaptoacetanilidas como inhibidores de la transcriptasa inversa del VIH
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
CN101083994A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
TW200626592A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7544672B2 (en) 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
MX2007013715A (es) 2005-05-05 2008-01-28 Ardea Biosciences Inc Diaril-purinas, azapurinas y deazapurinas como inhibidores no nucleosidos de transcriptasa inversa para el tratamiento del virus de inmunodeficiencia humana.
US8080555B2 (en) * 2005-05-16 2011-12-20 Prometic Biosciences Inc. Purine derivatives and their use for treatment of autoimmune diseases
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1991532B1 (en) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008058285A2 (en) 2006-11-09 2008-05-15 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
AR069753A1 (es) 2007-11-27 2010-02-17 Ardea Biosciences Inc Compuestos de 1,2,4-triazol y composiciones, utiles en la modulacion de los niveles de acido urico sanguineo
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011768A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011000839A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa.
WO2010017350A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
EP2427464A1 (en) 2009-05-06 2012-03-14 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
CN102712642B (zh) 2009-11-12 2015-08-12 霍夫曼-拉罗奇有限公司 N-7取代的嘌呤和吡唑并嘧啶化合物、组合物和使用方法
WO2011094290A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
WO2011094273A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
JP2013518113A (ja) 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピラジンキナーゼ阻害剤
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
US10016439B2 (en) 2014-01-31 2018-07-10 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
RU2716016C2 (ru) 2014-12-18 2020-03-05 Ниссан Кемикал Индастриз, Лтд. Соединение кетона или оксима и гербицид
AU2017345736B2 (en) * 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
EP3870568B1 (en) * 2018-10-25 2023-06-28 Minakem Process for the preparation of rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
CN114805369B (zh) * 2022-05-30 2023-05-16 自贡市第四人民医院(自贡市急救中心) 一种2，6-二取代嘌呤类化合物及制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
DK0945443T3 (da) 1998-03-27 2003-06-02 Janssen Pharmaceutica Nv HIV-hæmmende pyrimidinderivater
UA70966C2 (ru) * 1998-11-10 2004-11-15 Янссен Фармацевтика Н.В. Пиримидины, которые ингибируют репликацию вич
AU2217200A (en) * 1998-12-23 2000-07-12 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
DE60118521T2 (de) 2000-01-07 2006-10-12 Universitaire Instelling Antwerpen Purin derivate, ihre herstellung und verwendung
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6897307B2 (en) * 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
AU2004264419B2 (en) * 2003-08-15 2009-01-15 Irm Llc 6-substituted anilino purines as RTK inhibitors
MX2007013715A (es) * 2005-05-05 2008-01-28 Ardea Biosciences Inc Diaril-purinas, azapurinas y deazapurinas como inhibidores no nucleosidos de transcriptasa inversa para el tratamiento del virus de inmunodeficiencia humana.

Also Published As

Publication number Publication date
BRPI0414791A (pt) 2006-11-21
AP2006003517A0 (en) 2006-02-28
AU2004274185B2 (en) 2009-12-10
CN1856496A (zh) 2006-11-01
EP1668011A2 (en) 2006-06-14
KR20060121878A (ko) 2006-11-29
EP1668011B1 (en) 2011-03-02
MXPA06002069A (es) 2006-05-19
CA2535313A1 (en) 2005-03-31
WO2005028479A2 (en) 2005-03-31
TW200518758A (en) 2005-06-16
DE602004031641D1 (de) 2011-04-14
NO20061788L (no) 2006-04-24
ES2361835T3 (es) 2011-06-22
US8026245B2 (en) 2011-09-27
JP2012006945A (ja) 2012-01-12
JP5506751B2 (ja) 2014-05-28
EA009734B1 (ru) 2008-02-28
US20060293330A1 (en) 2006-12-28
ATE500254T1 (de) 2011-03-15
JP2007506707A (ja) 2007-03-22
ZA200602440B (en) 2007-09-26
JP4825672B2 (ja) 2011-11-30
AU2004274185A1 (en) 2005-03-31
WO2005028479A3 (en) 2005-06-16
IL174467A0 (en) 2006-08-01
CA2535313C (en) 2012-07-17
CN100475815C (zh) 2009-04-08

Similar Documents

Publication Publication Date Title
EA200600648A1 (ru) Производные пурина, ингибирующие репликацию вич
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
GB0612423D0 (en) Therapeutic agents
EA200501327A1 (ru) Пиримидины и триазины, ингибирующие вич репликацию
EA200601654A1 (ru) Ингибиторы интегразы вич
EA200600973A1 (ru) ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2
EA200600892A1 (ru) Новые хинолиновые производные
EA200970047A1 (ru) Водные суспензии тмс278
CY1110690T1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
CY1111693T1 (el) Αντιιικοι παραγοντες
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
GB0413087D0 (en) Therapeutic compounds
IL180495A (en) Benzyl triazolone compounds as non-nucleotide reverse transcriptase inhibitors
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
DE60324014D1 (de) Heterocyclische verbindungen alsccr5-antagonisten
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
UY27577A1 (es) Inhibidores de la integrasa del vih
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
NO20030297L (no) Aryl sulfonamider som serotoninantagonist for behandling av fedme
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM